Eyenuk’s AI Eye Screening System For Diabetic Retinopathy Demonstrates Exceptional Performance In A Prospective, Multi-Center, Pivotal Clinical Trial

Investigators Report the EyeArt System Achieved 95.5% Sensitivity, 86.5% Specificity and 97% Imageability, while Meeting All Primary Endpoints with p<0.0001LOS ANGELES — Eyenuk, Inc., a gl…